Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) CEO Milind Deshpande sold 216,624 shares of the company’s stock on the open market in a transaction dated Monday, August 18th. The shares were sold at an average price of $10.00, for a total transaction of $2,166,240.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Deutsche Bank upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday. They now have a $17.00 price target on the stock, up previously from $6.00. Separately, analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. Finally, analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. They set an “outperform” rating and a $12.00 price target on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. Achillion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $8.90.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 9.79 on Thursday. Achillion Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $10.18. The stock’s 50-day moving average is $7.49 and its 200-day moving average is $4.73. The company’s market cap is $957.3 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings data on Thursday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.69 earnings per share for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.